Mechanisms of Action of Nitrates

  • Kristina E. Torfgård
  • Johan Ahlner

Summary

Glyceryl trinitrate, isosorbide dinitrate, and isosorbide-5-mononitrate are organic nitrate esters commonly used in the treatment of angina pectoris, myocardial infarction, and congestive heart failure. Organic nitrate esters have a direct relaxant effect on vascular smooth muscles, and the dilation of coronary vessels improves oxygen supply to the myocardium. The dilation of peripheral veins, and in higher doses peripheral arteries, reduces preload and afterload, and thereby lowers myocardial oxygen consumption. Inhibition of platelet aggregation is another effect that is probably of therapeutic value. Effects on the central nervous system and the myocardium have been shown but not scrutinized for therapeutic importance. Both the relaxing effect on vascular smooth muscle and the effect on platelets are considered to be due to a stimulation of soluble guanylate cyclase by nitric oxide derived from the organic nitrate ester molecule through metabolization catalyzed by enzymes such as glutathione S-transferase, cytochrome P-450, and possibly esterases. The cyclic GMP produced by the guanylate cyclase acts via cGMP-dependent protein kinase. Ultimately, through various processes, the protein kinase lowers intracellular calcium; an increased uptake to and a decreased release from intracellular stores seem to be particularly important.

KeyWords

organic nitrate esters glyceryl trinitrate nitroglycerin isosorbide dinitrate isosorbide-5-mononitrate cyclic GMP 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murrel W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1879;1:80–81, 113–115, 151–152, 225–227.CrossRefGoogle Scholar
  2. 2.
    Axelsson KL, Andersson RGG, Wikberg JES, et al. Correlation between vascular smooth muscle relaxation and increase in cyclic GMP induced by some organic nitro esters. Acta Pharmacol Toxicol 1981;49:270–276.CrossRefGoogle Scholar
  3. 3.
    Torfgård K, Ahlner J, Axelsson KL, et al. Relaxation of bovine mesenteric arteries by glyceryl trinitrate and other stimulators of soluble guanylate cyclase. Evidence for different mechanisms of action. Pharmacol Toxicol 1990;67:216–221.PubMedCrossRefGoogle Scholar
  4. 4.
    Gumbleton M, Benet LZ. Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers. Br J Clin Pharmacol 1991;31:221–213.Google Scholar
  5. 5.
    Shibata T, Ogawa K, Ito T, et al. Role of cyclic GMP of canine vascular smooth muscle relaxation by organic nitroesters. Jpn Circ J 1986;50:1091–1099.PubMedCrossRefGoogle Scholar
  6. 6.
    Gharaibeh MN, Gross GJ. Comparative relaxant effects of nitroglycerin in isolated rings from various canine vascular beds. Gen Pharmacol 1984;15:217–221.PubMedGoogle Scholar
  7. 7.
    Miwa K, Toda N. The regional difference of relaxations induced by various vasodilators in isolated dog coronary and mesenteric arteries. Jpn J Pharmacol 1985;38:313–330.PubMedCrossRefGoogle Scholar
  8. 8.
    Mackenzie JE, Parratt JR. Comparative effects of glyceryl trinitrate on venous and arterial smooth muscle in vitro: Relevance to antianginal activity. Br J Pharmacol 1977;29:155–160.Google Scholar
  9. 9.
    Nakajima H, Nosaka K. A comparison of the effects of diltiazem and nitroglycerin on the norepinephrine-induced contractions in the isolated femoral artery and vein. Jpn J Pharmacol 1983;33:1282–1285.PubMedCrossRefGoogle Scholar
  10. 10.
    Toyoda J, Hisayama T, Takayanagi I. Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery. Gen Pharmacol 1986;17:89–91.PubMedGoogle Scholar
  11. 11.
    Rosen R, Konig E, Klaus W. Different sensitivities of arteries and veins to glyceryl trinitrate-induced relaxation and tolerance: An “in vitro” study on isolated vessels in rabbits. Arch Int Pharmacodyn Ther 1987;285:226–237.PubMedGoogle Scholar
  12. 12.
    Imhof PR, Ott B, Frankhauser P, et al. Differences in GTN dose-response in the venous and arterial beds. Eur J Clin Pharmacol 1980;18:455–460.PubMedCrossRefGoogle Scholar
  13. 13.
    Miller RR, Vismara LA, Williams D, et al. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure: Differential effects of nitroprusside, phentolamine and nitroglycerin on cardiac function and peripheral circulation. Circ Res 1976;39:127–133.PubMedGoogle Scholar
  14. 14.
    Gerson JL, Allen FB, Seitzer JL, et al. Arterial and venous dilation by nitroprusside and nitroglycerin—is there a difference? Anesth Analg (Cleve) 1982;61:256–260.Google Scholar
  15. 15.
    Toyoda J, Hisayama T, Takayanagi I. Effects of nitro compounds, isosorbide dinitrate, 5-isosobride mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries. Gen Pharmacol 1987;18:95–97.PubMedGoogle Scholar
  16. 16.
    Tadjkarimi S, O’Neil GS, Luu TN, et al. Comparison of cyclic GMP in human internal mammary artery and saphenous vein: Implications for coronary artery bypass graft patency. Cardiovasc Res 1992;26:297–300.PubMedCrossRefGoogle Scholar
  17. 17.
    Fung H-L, Sutton SC, Kamiya A. Blood vessel uptake and metabolism of organic nitrates in the rat. J Pharmacol Exp Ther 1984;228:334–341.PubMedGoogle Scholar
  18. 18.
    Kawamoto JH, Brien JF, Marks GS, et al. A comparative study of glyceryl trinitrate biotransformation and glyceryl trinitrate induced relaxation in bovine pulmonary artery and vein. Can J Physiol Pharmacol 1987;65:1146–1150.PubMedCrossRefGoogle Scholar
  19. 19.
    Torfgård KE. Glyceryl Trinitrate Distribution and the “Remarkable Tolerance.” Linkbping University Medical Dissertations No. 358, Linkbping, 1992, pp 1–68.Google Scholar
  20. 20.
    Ahlner J, Axelsson KL, Ekstam Ljusegren M, et al. Demonstration of a high affinity component of glyceryl trinitrate induced vasodilation in the bovine mesenteric artery. J Cyclic Nucl Prot Phosphoryl Res 1987;11:445–456.Google Scholar
  21. 21.
    Dinerman JL, Lawson DL, Metha JL. Interactions between nitroglycerin and endothelium in vascular smooth muscle relaxation. Am J Physiol 1991;260:H698–H701.PubMedGoogle Scholar
  22. 22.
    Moncada S, Rees DD, Schulz R, et al. Development and the mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 1991;88:2166–2170.PubMedCrossRefGoogle Scholar
  23. 23.
    Eichler H-G, Hiremath A, Katzir D, et al. Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clin Pharmacol Ther 1987;42:521–524.PubMedCrossRefGoogle Scholar
  24. 24.
    Feldman RL, Pepine CJ, Curry RC, et al. Coronary arterial responses to graded doses of nitroglycerin. Am J Cardiol 1979;43:91–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Brown BG, Bolson E, Petersen RB. The mechanism of nitroglycerin action: Stenosis dilation as a major component of drug response. Circulation 1981;64:1089–1097.PubMedCrossRefGoogle Scholar
  26. 26.
    Sievert H, Selzer G, Schneider W, et al. Coronary stenosis dilation by low dose intravenous nitroglycerin. Eur Heart J 1989;10:134–136.PubMedGoogle Scholar
  27. 27.
    Sellke FW, Myers PR, Bates JN, et al. Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. Am J Physiol 1990;258:H515–H520.PubMedGoogle Scholar
  28. 28.
    Kurz MA, Boyer TD, Whalen R, et al. Nitroglycerin metabolism in vascular tissue: Role of gluathione S-transferases and relationship between NO- and NO2- formation. Biochem J 1993;292:545–550.PubMedGoogle Scholar
  29. 29.
    Schaffer AI, Alexander RW, Handin RI. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980;55:649–654.Google Scholar
  30. 30.
    Loscalzo J. N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985;76:703–708.PubMedCrossRefGoogle Scholar
  31. 31.
    Ahlner J, Andersson RGG, Axelsson KL, et al. Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. Acta Pharmacol Toxicol 1985;57:88–95.CrossRefGoogle Scholar
  32. 32.
    Chirkov YY, Naujalis Ji, Barber S, et al. Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol 1992;70:802–806.PubMedCrossRefGoogle Scholar
  33. 33.
    Chirkov YY, Belushkina NN, Tyshchuk IA, et al. Increase in reactivity of human platelet guanylate cyclase during aggregation portentiates the disaggregating capacity of sodium nitroprusside. Clin Exp Pharmacol Physiol 1991; 18:517–524.PubMedCrossRefGoogle Scholar
  34. 34.
    De Caterina R, Giannessi D, Crea F, et al. Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol 1984;53:1683–1687.PubMedCrossRefGoogle Scholar
  35. 35.
    De Caterina R, Lombardi M, Bernini W, et al. Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: Relationship between plasma durg concentration and hemodynamic effects. Am Heart J 1990;119:855–862.PubMedCrossRefGoogle Scholar
  36. 36.
    Diodati J, Theroux P, Latour JG, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol 1990;66:683–688.PubMedCrossRefGoogle Scholar
  37. 37.
    Karlberg K-E, Torfgård K, Ahlner J, et al. Dose-dependent effect of intravenous nitroglycerin on platelet aggregation, and correlation with plasma glyceryl dinitrate concentration in healthy men. Am J Cardiol 1992;69:802–805.PubMedCrossRefGoogle Scholar
  38. 38.
    Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. Circulation 1988;78:712–716.PubMedCrossRefGoogle Scholar
  39. 39.
    Brodie A, Chuck L, Klausner S, et al. Effects of sodium nitroprusside and nitroglycerin on tension prolongation of cat papillary muscle during recovery from hypoxia. Circ Res 1976;39:596–601.PubMedGoogle Scholar
  40. 40.
    Barath P, Kekes E, Strausz J. Acute global ischaemia and nitroglycerin-induced changes of the contraction-relaxation and diastolic properties of isolated rabbit heart. Acta Physiol Pol 1981;32:637–649.PubMedGoogle Scholar
  41. 41.
    Strauer BE, Westberg C, Tauchert M. Untersuchungen Uber inotrope Nitroglycerinwirkungen am isolierten Ventrikelmyokard. Pjlugers Arch 1971;324:124–133.CrossRefGoogle Scholar
  42. 42.
    Himori N, Imai Y, Taira N. Positive inotropic action of glyceryl trinitrate as observed in the blood-perfused papillary muscle preparation of the dog heart. Clin Exp Pharmacol Physiol 1977;4:257–262.PubMedCrossRefGoogle Scholar
  43. 43.
    Atanassova R, Spassov G, Balansky R, et al. Effects of isosorbide-5-mononitrate and isosorbide-2-mononitrate on the contractile and electrical activity and on the content of cyclic nucleotides in isolated heart muscles of the guineapig and dog. J Pharm Pharmacol 1992;44:663–666.PubMedCrossRefGoogle Scholar
  44. 44.
    Laustiola K, Vuorinen P, Vapaatalo H, et al. Effects of cysteine and nitroglycerin on bovine heart guanylate cyclase and on tissue cyclic GMP and lacate of rat atria. Eur J Pharmacol 1983;91:301–304.PubMedCrossRefGoogle Scholar
  45. 45.
    Ekstam Ljusegren M, Asplund A, Axelsson KL. Oxygen consumption in isolated hypoxic rat ventricular myocardium. Effect of different modulators of the cyclic GMP system. Pharmacol Toxicol, 1993, submitted.Google Scholar
  46. 46.
    Ahlner J. Andersson RGG, Torfgård K, et al. Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol Rev 1991;43:351–423.PubMedGoogle Scholar
  47. 47.
    Iversen HK. N-acetylcystein enhances nitroglycerin-induced headache and cranial arterial response. Clin Pharmacol Ther 1992;52:125–133.PubMedCrossRefGoogle Scholar
  48. 48.
    Torfgård K, Ahlner J, Axelsson KL, et al. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol 1989;64:369–372.PubMedCrossRefGoogle Scholar
  49. 49.
    Marks GS, McLaughlin BE, Nakatsu K, et al. Biotransformation of glyceryl trinitrate by rat brain homogenate. Can J Physiol Pharmacol 1992;70:935–937.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaverina NV. The mechanism of nitroglycerin action on the cardiac vessels. Bull Exp Biol Med 1960;49:75–78.CrossRefGoogle Scholar
  51. 51.
    Kaverina NV, Vysotskaya NB, Rosonov YUB, et al. Connection between central action of glyceryl trinitrate and monoamine metabolism of the brain. Bull Exp Biol Med 1967;64:1310–1313.CrossRefGoogle Scholar
  52. 52.
    Ma SX, Long JP. Central noradrenergic activity is responsible for nitroglycerin-induced cardiovascular effects in the nucleus tractus solitarii. Brain Res 1991;559;297–303.PubMedCrossRefGoogle Scholar
  53. 53.
    Ma SX, Long JP, Bhatnagar RK. Further studies on central actions of nitroglycerin and lack of evidence for nitroglycerin interacting on [3H]clonidine binding sites in cortex membranes. J Pharmacol Exp Ther 1992;261:1187–1194.PubMedGoogle Scholar
  54. 54.
    Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057–1058.PubMedCrossRefGoogle Scholar
  55. 55.
    Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651–4655.PubMedCrossRefGoogle Scholar
  56. 56.
    Boulanger C, Liischer TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587–590.PubMedCrossRefGoogle Scholar
  57. 57.
    Nakai T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990; 1898:347–353.Google Scholar
  58. 58.
    Yates MT, Lambert LE, Whitten JP, et al. A protective role for nitric oxide in the oxidative modification of low density lipoproteins by mouse macrophages. FEBS Lett 1992;309:135–138.PubMedCrossRefGoogle Scholar
  59. 59.
    Duarte IDG, Dos Santos IR, Lorenzetti BB, et al. Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 1992;217:225–227.PubMedCrossRefGoogle Scholar
  60. 60.
    Ferreira SH, Lorenzetti BB, Faccioli LH. Blockade of hyperalgesia and neurogenic oedema by topical application of nitroglycerin. Eur J Pharmacol 1992;217:207–209.PubMedCrossRefGoogle Scholar
  61. 61.
    Needleman P, Jakschik B, Johnson EM. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187:324–331.PubMedGoogle Scholar
  62. 62.
    Schror K, Grodzinska L, Darius H. Stimulation of coronary vascular prostacyclin and inhibition of human platelet thromboxane A2 after low-dose nitroglycerin. Thromb Res 1981; 23:59–67.PubMedCrossRefGoogle Scholar
  63. 63.
    Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K. Nitroglycerin stimulates synthesis of prostaglandin by cultured human endothelial cells. J Clin Invest 1981;67:762–769.PubMedCrossRefGoogle Scholar
  64. 64.
    Bennett BM, Moffat JA, Armstrong PW, Marks GS. Investigation of the role of prostaglandins in nitroglycerin-induced relaxation of isolated rabbit blood vessels. Can J Physiol Pharmacol 1983:61:554–560.PubMedCrossRefGoogle Scholar
  65. 65.
    Rehr RB, Jackson JA, Winniford MD, et al. Mechanism of nitroglycerin-induced coronary dilatation. Lack of relation to intracoronary thromboxane concentrations. Am J Cardiol 1984;54:971–974.PubMedCrossRefGoogle Scholar
  66. 66.
    DeCaterina R, Dorso CR, Tack-Goldman K, Weksler BB. Nitrates and endothelial prostacyclin production: Studies in vitro. Circulation 1985;71:176–182.PubMedCrossRefGoogle Scholar
  67. 67.
    Bornfeldt KE, Axelsson KL. Studies on the effect of different inhibitors of arachidonic acid metabolism on glyceryl-trinitrate-induced relaxation and cGMP elevation in bovine vascular tissue. Pharmacol Toxicol 1987;60:110–116.PubMedCrossRefGoogle Scholar
  68. 68.
    Malta E. Studies on the biphasic relaxant curves of glyceryltrinitrate in rat aorta: Role of GTN metabolism. Clin Exp Pharmacol Physiol 1989;16:829–836.PubMedCrossRefGoogle Scholar
  69. 69.
    Hamaguchi M, Ishibashi T, Imai S. Involvement of charybdotoxin-sensitive K+ channel in the relaxation of bovine tracheal smooth muscle by glyceryl trinitrate and sodium nitroprusside. J Pharmacol Exp Ther 1992;262:263–270.PubMedGoogle Scholar
  70. 70.
    Williams DL, Katz GM, Roy-Contancin L, et al. Guanosine 5′-monophosphate modulates gating of high-conductance Ca2+-activated K+ channels in vascular smooth muscle cell. Proc Natl Acad Sci USA 1988;85:9360–9364.PubMedCrossRefGoogle Scholar
  71. 71.
    Fujino K, Nakaya S, Wakatsuki T, et al. Effects of nitroglycerin on ATP-induced Ca+-mobilization, Ca+-activated K channels and contraction of cultured smooth muscle cells of porcine coronary artery. J Pharmacol Exp Ther 1991; 256:371–377.PubMedGoogle Scholar
  72. 72.
    Imai S, Takeda K. Effect of vasodilators upon the isolated taenia coli of the guinea pig. J Pharmacol Exp Ther 1967;156:557–564.PubMedGoogle Scholar
  73. 73.
    Ito Y, Kitamura K, Kuriyama H. Actions of nitroglycerin on the membrane and mechanical properties of smooth muscles of the coronary artery in the pig. Br J Pharmacol 1980;70:197–204.PubMedGoogle Scholar
  74. 74.
    Karashima S. Actions of nitroglycerin on smooth muscles of guinea-pig and rat portal veins. Br J Pharmacol 1980; 71:489–497.PubMedGoogle Scholar
  75. 75.
    Tare M, Parkington HC, Coleman HA, et al. Hyperpolarisation and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature 1990;346:69–71.PubMedCrossRefGoogle Scholar
  76. 76.
    Stiefel A, Kreye VAW. On the hemodynamic differences between sodium nitroprusside, nitroglycerin, and isosorbide dinitrates. Comparison of their vasorelaxant effects in vitro and their inactivation in vivo. Naunyn Schmiedebergs Arch Pharmacol 1984;325;270–274.PubMedCrossRefGoogle Scholar
  77. 77.
    Schneeweiss A. Comparative evaluation of isosorbide-5-mononitrate and nitroglycerin in chronic congestive heart failure. Am J Cardiol 1988;61:19E–21E.PubMedCrossRefGoogle Scholar
  78. 78.
    Schneider W, Tessmer G, Strohm WD, et al. Die Weite von arteriellen und venosen Abdominalgefassen unter akuter und chronischer Gabe von Nitraten. Eine sonographische Untersuchung. Z Kardiol 1986;75:296–302.PubMedGoogle Scholar
  79. 79.
    Roth A, Weber L, Friedenberger L, et al. Hemodynamic effects of intravenous isosorbide dinitrate and nitroglycerin in acute myocardial infarction and elevated pulmonary artery wedge pressure. Chest 1987;91:190–196.PubMedCrossRefGoogle Scholar
  80. 80.
    Bennet BM, Hayward LD, Murad F. Effects of the D and L stereoisomers of isosorbide dinitrate on relaxation and cyclic GMP accumulation in rat aorta and comparison to glyceryl trinitrate. J Appl Cardiol 1986;1:200–209.Google Scholar
  81. 81.
    Bennet BM, Schroder H, Hayward LD, et al. Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation, and guanylate cyclase activation by glyceryl trinitrate and the enantiomers of isosorbide dinitrate. Circ Res 1988;63:693–701.Google Scholar
  82. 82.
    Axelsson KL, Anderson C, Ahlner J, et al. Comparative in vitro study of a series of organic nitroesters: Unique biphasic concentration-effect curves for glyceryl trinitrate in isolated bovine arterial smooth muscle and lack of stereo-selectivity for some glyceryl trinitrate analogues. J Cardiovasc Pharmacol 1992;19:953–957.PubMedCrossRefGoogle Scholar
  83. 83.
    Kamitani T. Inhibitory effect of Ca2+ on nitroglycerin-induced vasodilatation. Eur J Pharmacol 1984;100:145–154.PubMedCrossRefGoogle Scholar
  84. 84.
    Ahlner J, Andersson RGG, Axelsson KL, et al. Development of tolerance towards glyceryl trinitrate in vitro. Low concentration induced tolerance and changes in cyclic guanosine-3′,5′-monophosphate metabolism. Arzneim Forsch Durg Res 1987;37:914–916.Google Scholar
  85. 85.
    Malta E. Biphasic relaxant curves to glyceryl trinitrate in rat aortic rings. Evidence for two mechanisms of action. Naunyn Schmiedebergs Arch Pharmacol 1989;339:236–243.PubMedCrossRefGoogle Scholar
  86. 86.
    Axelsson KL, Ahlner J, Torfgård K. Effects of pertussis toxin and the cGMP 1 lowering agent LY83583 on the relaxation induced by nitrates in isolated bovine mesenteric artery. A comparison between glyceryl trinitrate, ISDN and isosorbide-5 mononitrate. Z Kardiol 1989;78(Suppl 2):11–13.PubMedGoogle Scholar
  87. 87.
    Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosorthiols as active intermediates. J Pharmacol Exp Ther 1981;218:739–749.PubMedGoogle Scholar
  88. 88.
    Fung H-L, Chong S, Kowaluk E, et al. Mechanisms for the pharmacologic interaction of organic nitrates with thiols. Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcystein. J Pharmacol Exp Ther 1988;245:524–530.PubMedGoogle Scholar
  89. 89.
    Chung S-J, Fung H-L. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther 1990;253:614–619.PubMedGoogle Scholar
  90. 90.
    Brien JF, McLaughlin BE, Kubos SM, et al. Mechanism of glyceryl trinitrate-induced vasodilation. I. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. J Pharmacol Exp Ther 1988;244:322–327.PubMedGoogle Scholar
  91. 91.
    Noonan PK, Benet LZ. Formation of mono- and dinitrate metabolities of nitroglycerin following incubation with human blood. Int J Pharm 1982;12:331–340.CrossRefGoogle Scholar
  92. 92.
    Cossum PA, Roberts MS. Nitroglycerin Disposition in human blood. Eur J Clin Pharmacol 1985;29:169–175.PubMedCrossRefGoogle Scholar
  93. 93.
    Tarn GS, Marks G, Brien JF, Nakatsu K. Sex- and species-related differences in the biotransformation of isosorbide dinitrate by various tissues of the rabbit and rat. Can J Physiol Pharmacol 1987;65:1478–1483.CrossRefGoogle Scholar
  94. 94.
    Chong S, Fung H-L. Thiol-mediated catalysis of nitroglycerin degradation by serum proteins. Increase in metabolism was not accompanied by S-nitrosothiol production. Drug Metab Dispos 1990;18:61–67.PubMedGoogle Scholar
  95. 95.
    Cossum PA, Robers MS, Yong AC, Kilpatrick D. Distribution and metabolism of nitroglycerin and its metabolites in vascular beds of sheep. J Pharmacol Exp Ther 1986; 237:959–966.PubMedGoogle Scholar
  96. 96.
    Tarn GS, MacMillan H, Bennett BM, Marks GS, Brien JF, Nakatsu K. Patterns of isosorbide dinitrate and glyceryl trinitrate metabolites formed by selected segments of rabbit gastrointestinal tract. Can J Physiol Pharmacol 1988; 66:166–170.CrossRefGoogle Scholar
  97. 97.
    Sellke FW, Tomanek RJ, Harrison DG. L-cysteine selectivity potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharmacol Exp Ther 1991;258:365–369.PubMedGoogle Scholar
  98. 98.
    Chong S, Fung H-L. Kinetic mechanisms for the concentration dependency of in vitro degradation of nitroglycerin and glyceryl dinitrates in human blood. Metabolite inhibition or co-substrate depletion? J Pharm Sci 1989;78:295–302.PubMedCrossRefGoogle Scholar
  99. 99.
    Hill KE, Hunt RW, Jones R, et al. Metabolism of nitroglycerin by smooth muscle cells. Biochem Pharmacol 1992;43:561–566.PubMedCrossRefGoogle Scholar
  100. 100.
    Chung S-J, Chong S, Seth P, et al. Conversion of nitroglycerin to nitric oxide in microsomes of the bovine coronary artery smooth muscle is not primarily mediated by glutathione-S-transferases. J Pharmacol Exp Ther 1992;260:652–659.PubMedGoogle Scholar
  101. 101.
    Chung S-J, Fung H-L. A common enzyme may be responsible for the coversion of organic nitrates to nitric oxide in vascular microsomes. Biochem Biophys Res Commun 1992;185:932–937.PubMedCrossRefGoogle Scholar
  102. 102.
    Seth P, Fung H-L. Biochemical characterization of a membrane bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol 1993;46:1481–1486.PubMedCrossRefGoogle Scholar
  103. 103.
    Sakanashi M, Matsuzaki T, Aniya Y. Nitroglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathione S-transferase activity. Br J Pharmacol 1991;103:1905–1908.PubMedGoogle Scholar
  104. 104.
    Chung S-J, Fung H-L. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production. Probes with inhibitors and tolerance development. Biochem Pharmacol 1993;45:157–163.PubMedCrossRefGoogle Scholar
  105. 105.
    Lau DT-W, Benet LZ. Nitroglycerin metabolism in subcellular fractions of rabbit liver. Dose dependency of glyceryl dinitrate formation and possible involvement of multiple enzymes of glutathione S-transferases. Drug Metab Dispos 1990;181:489–497.Google Scholar
  106. 106.
    Marcus CJ, Habig WH, Jakobi WB. Glutathione transferase from human erythrocytes. Arch Biochem Biophys 1978;188:287–293.PubMedCrossRefGoogle Scholar
  107. 107.
    Tsuchida S, Maki T, Sato K. Purification and characterization of glutathione transferase with an activity toward nitroglycerin from human aorta and heart. J Biol Chem 1990; 265:7150–7157.PubMedGoogle Scholar
  108. 108.
    Lau DT-W, Benet LZ. Effect of sulfobromophtalein and ethacrynic acid on glyceryl trinitrate relaxation. Biochem Pharmacol 1992;43:2247–2254.PubMedCrossRefGoogle Scholar
  109. 109.
    Yeates RA, Schmid M, Leitold M. Antagonist of glyceryl trinitrate activity by inhibitors of glutathione-S-transferase. Biochem Pharmacol 1989;38:1749–1753.PubMedCrossRefGoogle Scholar
  110. 110.
    Nigam R, Whiting T, Bennett BM. Effect of glutathione S-transferase on glyceryl trinitrate actvity in isolated rat aorta. Can J Physiol Pharmacol 1993;71:179–184.PubMedCrossRefGoogle Scholar
  111. 111.
    Servent D, Delaforge M, Ducrocq C, et al. Nitric formation during microsomal hepatic denitration of glyceryl trinitrate: Involvement of cytochrome P-450. Biochem Biophys Res Commun 1989;163:1210–1216.PubMedCrossRefGoogle Scholar
  112. 112.
    McDonald BJ, Bennett BM. Cytochrome P-450 mediated biotransformation of organic nitrates. Can J Physiol Pharmacol 1990;68:1552–1557.PubMedCrossRefGoogle Scholar
  113. 113.
    Abraham NG, Pinto A, Mullane KM, et al. Presence of cytochrome P-450-dependent monooxygenase in intimal cells of the hog aorta. Hypertension 1985;7:899–904.PubMedGoogle Scholar
  114. 114.
    Liu Z, Brien F, Marks GS, et al. Lack of evidence for the involvement of cytochrome P-450 or other hemoproteins in metabolic activations of glyceryl trinitrate in rabbit aorta. J Pharmacol Exp Ther 1993;264:1432–1439.PubMedGoogle Scholar
  115. 115.
    Bennett BM, McDonald BJ, Nigam R, et al. Inhibition of nitrovasodilator- and acetylcholine-induced relaxation and cyclic GMP accumulation by the cytochrome P-450 substrate, 7-ethoxyresorufin. Can J Physiol Pharmacol 1993;70:1297–1303.CrossRefGoogle Scholar
  116. 116.
    Schroder H, Schror K. Inhibitors of cytochrome P-450 reduce cyclic GMP stimulation of glyceryl trinitrate in LLCPK1 kidney epithelial cells. Naunyn-Schmiedebergs Arch Pharmacol 1990;342:616–618.PubMedGoogle Scholar
  117. 117.
    Schroder H. Cytochrome P-450 mediates bioactivation of organic nitrates. J Pharmacol Exp Ther 1992;262:298–302.PubMedGoogle Scholar
  118. 118.
    Bennett BM, McDonald BJ, St. James MJ. Hepatic cytochrome P-450-mediated activation of rat aortic guanylyl cyclase by glyceryl trinitrate. J Pharmacol Exp Ther 1992;261:716–723.PubMedGoogle Scholar
  119. 119.
    Williams FM. Clinical significance of esterases in man. Clin Pharmacokin 1985;10:392–403.CrossRefGoogle Scholar
  120. 120.
    Noak E. Investigation on structure-activity relationship in organic nitrates. Meth Exp Clin Pharmacol 1984;6:583–586.Google Scholar
  121. 121.
    Chhajlani V, Axelsson KL, Ahlner J, et al. Purification of soluble guanylate cyclase enzyme from human platelets. Biochemlnt 1989;19:1039–1044.Google Scholar
  122. 122.
    Kamisaki Y, Saheki S, Nakane M, et al. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem 1986;261:7236–7241.PubMedGoogle Scholar
  123. 123.
    Koesling D, Herz J, Gausepohl H, et al. The primary structure of the 70 kDa subunit of bovine soluble guanylate cyclase. FEBS Lett 1988;239:29–34.PubMedCrossRefGoogle Scholar
  124. 124.
    Nakane M, Arai K, Saheki S, et al. Molecular cloning and expression of cDNAs coding for soluble guanylate cyclase from rat lung. J Biol Chem 1990;265:16841–16845.PubMedGoogle Scholar
  125. 125.
    Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun 1991;174:351–357.PubMedCrossRefGoogle Scholar
  126. 126.
    Gerzer R, Bohme E, Hofmann F, et al. Soluble guanylate cyclase purified from bovine lung contains copper and heme. FEBS Lett 1981;132:71–74.PubMedCrossRefGoogle Scholar
  127. 127.
    Gerzer R, Radany EW, Garbers DL. The separation of the heme and apoheme forms of soluble guanylate cyclase. Biochem Biophys Res Commun 1982;108:678–686.PubMedCrossRefGoogle Scholar
  128. 128.
    Kon H, Kataoka N. Electron paramagnetic resonance of nitric oxide-protoheme complexes with some nitrogenous base. Model systems of nitric oxide hemoproteins. Biochemistry 1969;8:4757–4762.PubMedCrossRefGoogle Scholar
  129. 129.
    Morse RH, Chan SI. Electron paramagnetic resonance studies of nitrosyl ferrous heme complexes. Determination of an equilibrium between two conformations. J Biol Chem 1980;255:7876–7882.PubMedGoogle Scholar
  130. 130.
    Wolin MS, Wook KS, Ignarro LJ. Guanylate cyclase from bovine lung. A kinetic analysis of the regulation of the unpurified soluble enzyme by protoporphyrin IX, heme, and nitrosyl-heme. J Biol Chem 1982;257:13312–13320.PubMedGoogle Scholar
  131. 131.
    Ignarro LJ, Wood KS, Wolin KS. Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: A unifying concept. Adv Cycl Nucl Prot Phosphoryl Res 1984;17:267–274.Google Scholar
  132. 132.
    Craven PA, DeRubertis FR. Effects of thiol inhibitors on hepatic guanylate cyclase activity. Evidence for the involvement of vicinal dithiols in the expression of basal and agonist-stimulated activity. Biochim Biophys Acta 1978a; 524:231–244.Google Scholar
  133. 133.
    Ignarro LJ, Kadowitz PJ, Baricos WH. Evidence that regulation of hepatic guanylate cyclase activity involves interactions between catalytic site-SH groups and both substrate and activator. Arch Biochem Biophys 1981;208;75–86.PubMedCrossRefGoogle Scholar
  134. 134.
    Heppel LA, Hilmoe RJ. Metabolism of inorganic nitrite and nitrate esters. II. The enzymatic reduction of nitroglycerin and erythritoltetranitrate by glutathione. J Biol Chem 1950;183:129–138.Google Scholar
  135. 135.
    Ignarro LJ, Edwards JC, Gruetter DY, et al. Possible involvement of S-nitrosothiols in the activation guanylate cyclase by nitroso compounds. FEBS Lett 1980;110:275–278.PubMedCrossRefGoogle Scholar
  136. 136.
    Ignarro LJ, Gruetter CA. Requriements of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of S-nitrosothiols. Biochem Biophs Acta 1980;631:221–231.Google Scholar
  137. 137.
    Craven PA, DeRubertis FR. Restoration of responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. J Biol Chem 1978;253:8433–8443.PubMedGoogle Scholar
  138. 138.
    Craven PA, DeRubertis FR. Requirement for heme in the activation of purified guanylate cyclase by nitric oxide. Biochem Biophys Acta 1983;745:310–321.PubMedCrossRefGoogle Scholar
  139. 139.
    Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sci 1990,11:150–155.PubMedCrossRefGoogle Scholar
  140. 140.
    Weishaar RE, Burrows SD, Kobylarz DC, et al. Multiple forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 1986;35:787–800.PubMedCrossRefGoogle Scholar
  141. 141.
    Gillespie PG, Beavo JA. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol Pharmacol 1989;36:773–781.PubMedGoogle Scholar
  142. 142.
    Sutherland EW, Robison GA, Butcher RW. Some aspects of the biological role of adenosine-3′,5′-monophosphate (cyclic AMP). Circulation 1968;37:279–306.Google Scholar
  143. 143.
    Kobayashi A, Suzuki Y, Kamikawa T, et al. The effects of nitroglycerin on cyclic nucleotides in the coronary artery in vivo. Life Sci 1980;27:1679–1685.PubMedCrossRefGoogle Scholar
  144. 144.
    Kukovetz WR, Holzmann S, Wurm A, et al. Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 1979;310:129–138.PubMedCrossRefGoogle Scholar
  145. 145.
    Holzmann S. Endothelium-induced relaxation by acetylcholine associated with larger rises in cyclic GMP in coronary arterial strips. J Cycl Nucl Prot Phosphoryl Res 1982;8:409–419.Google Scholar
  146. 146.
    Ahlner J, Andersson RGG, Axelsson KL, et al. Development of tolerance to glyceryl trinitrate in an isolated human peripheral vein and its relation to cyclic GMP metabolism. Acta Pharmacol Toxicol 1986;59:123–128.Google Scholar
  147. 147.
    Schultz K-D, Bohme E, Kreye VAW, et al. Relaxation of hormonally stimulated smooth muscular tissues by the 8-bromoderivative of cyclic GMP. Naunyn Schmiedebergs Arch Pharmacol 1979;306:1–9.PubMedCrossRefGoogle Scholar
  148. 148.
    Napoli SA, Gruetter CS, Ignarro LJ, et al. Relaxation of bovine coronary arterial smooth muscle by cyclic GMP, cyclic AMP and analogs. J Pharmacol Exp Ther 1980;212:469–473.PubMedGoogle Scholar
  149. 149.
    Axelsson KL. Studies on the Action of Organic Nitroesters in Vascular Smooth Muscle with Special Reference to Cyclic GMP Metabolism. Linkoping University Medical Dissertations no. 179, Linkoping 1984, pp 1–58.Google Scholar
  150. 150.
    Saeed M, Schmidli J, Metz M, et al. The effect of 8-bromo-cyclic GMP on rabbit vascular smooth muscle. Curr Ther Res 1987;41:199–209.Google Scholar
  151. 151.
    Axelsson KL, Karlsson JOG. Nitroglycerin tolerance in vitro: Effect on cGMP turnover in vascular smooth muscle. Acta Pharmacol Toxicol 1984;55:203–210.CrossRefGoogle Scholar
  152. 152.
    Romanin C, Kukovetz WR. Guanylate cyclase activation by organic nitrates is not mediated via nitrite. J Mol Cell Cardiol 1988;20:389–396.PubMedCrossRefGoogle Scholar
  153. 153.
    Milligan G. Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins. Biochem J 1988;255:1–13.PubMedGoogle Scholar
  154. 154.
    Reisine T. Pertussis toxin in the analysis of receptor mechanisms. Biochem Pharmacol 1990;39:1499–1504.PubMedCrossRefGoogle Scholar
  155. 155.
    Ahlner J, Axelsson KL, Ekstam Ljusegren M, et al. Relaxation of bovine mesenteric artery induced by glyceryl trinitrate is attenuated by pertussis toxin. Pharmacol Toxicol 1988;62:155–158.PubMedCrossRefGoogle Scholar
  156. 156.
    Lobban M, Van Heyningen S. Thiol reagents are substrates for the ADP-ribosyltransferase activity of pertussis toxin. FEBS Lett 1988;233;229–232.PubMedCrossRefGoogle Scholar
  157. 157.
    Yuen PST, Potter LR, Garbers DL. A new form of guanylyl cyclase is preferentially expressed in rat kidney. Biochemistry 1990;29:10872–10878.PubMedCrossRefGoogle Scholar
  158. 158.
    Chhajlani V, Frandberg PA, Ahlner J, et al. Heterogeneity in human soluble guanylate cyclase due to alternative splicing. FEBS Lett 1991;290:157–158.PubMedCrossRefGoogle Scholar
  159. 159.
    Lad PJ, White AA. Activation of particulate guanylate cyclase by nitroprusside and MNNG after filipin treatment. J Cycl Nucl Res 1979;5:315–325.Google Scholar
  160. 160.
    Waldman SA, Lewicki JA, Brandwein HJ, et al. Partial purification and characterization of particulate guanylate cyclase from rat liver after solubilization with trypsin. J Cycl Nucl Res 1982;8:359–370.Google Scholar
  161. 161.
    Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163–196.PubMedGoogle Scholar
  162. 162.
    Epstein SA, Giannella RA, Brandwein HJ. Activation of guanylate cyclase by E. coli heat-stable enterotoxin (STa). FEBS Lett 1986;203:44–48.PubMedGoogle Scholar
  163. 163.
    Cornwell TL, Pryzwansky KB, Wyatt TA, Lincoln TM. Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells. J Pharmacol Exp Ther 1991;40:923–931.Google Scholar
  164. 164.
    Stamler J, Cunningham M, Loscalzo J. Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. Am J Cardiol 1988;62:377–380.PubMedCrossRefGoogle Scholar
  165. 165.
    Takai Y, Kaibuchi K, Matsubara T, et al. Inhibitory action of guanosine 3′,5′-monophosphate on thrombin-induced phosphatidylinositol turnover and protein phosphorylation in human platelets. Biochem Biophys Res Commun 1981; 101;61–67.PubMedCrossRefGoogle Scholar
  166. 166.
    Yamanishi J, Tajai Y, Kaibuchi K, et al. Synergistic functions of phorbol ester and calcium in serotonin release from human platelets. Biochem Biophys Res Commun 1983;112:778–786.PubMedCrossRefGoogle Scholar
  167. 167.
    Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482–1489.PubMedCrossRefGoogle Scholar
  168. 168.
    Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 1988;85:2800–2804.PubMedCrossRefGoogle Scholar
  169. 169.
    Groves PH, Penny WJ, Cheadle HA, et al. Exogenous nitric oxide inhibits in vivo platelet adhesion following balloon angioplasty. Cardiovasc Res 1992;26:615–619.PubMedCrossRefGoogle Scholar
  170. 170.
    Venturini CM, Weston LK, Kaplan JE. Platelet cGMP, but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am J Physiol 1992;263:H606–H612.PubMedGoogle Scholar
  171. 171.
    Lieberman EH, O’Neill S. Mendelsohn ME. S-Nitrosocysteine inhibition of human platelet secretion is correlated with increases in platelet cGMP levels. Circ Res 1991;68:1722–1728.PubMedGoogle Scholar
  172. 172.
    Drummer C, Ludke S, Spannagl M, et al. The nitric oxide donor SIN-1 is a potent inhibitor of plasminogen activator inhibitor release from stimulated platelets. Thronmb Res 1991;63:553–556.CrossRefGoogle Scholar
  173. 173.
    Eigenthaler NM, Nolte C, Halbrügge M, et al. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Eur J Biochem 1992;205:471–481.PubMedCrossRefGoogle Scholar
  174. 174.
    Laustiola K, Vuorinen P, Karp M, et al. 8-Bromo cyclic GMP inhibits NADH and lactate accumulation in hypoxic rat atria. Naunyn Schmiedebergs Arch Pharmacol 1983,323:361–363.PubMedCrossRefGoogle Scholar
  175. 175.
    Laustiola K, Vuorinen P, Vapaatalo H, et al. Sodium nitroprusside inhibits lactate formation in rat atria: Is cyclic GMP involved? Acta Pharmacol Toxicol 1983;52:195–200.CrossRefGoogle Scholar
  176. 176.
    Vuorinen P, Laustiola K, Metsä-Ketelä T. The effects of cyclic AMP and cyclic GMP on redox state and energy state in hypoxic rat atria. Life Sci 1984;35:155–161.PubMedCrossRefGoogle Scholar
  177. 177.
    Laustiola K, Vuorinen P, Metsä-Ketelä T. 8-Bromo-cGMP improves energy state in hypoxic rat atria. Acta Pharmacol Toxicol 1984;55:21–24.CrossRefGoogle Scholar
  178. 178.
    Laustiola K. Cyclic GMP affects redox state and improves energy charge of ischemic Langendorf-perfused rat heart. Acta Pharmacol Toxicol 1985;56:139–143.CrossRefGoogle Scholar
  179. 179.
    Ekstam Ljusegren M, Axelsson KL. Lactate accumulation in isolated hypoxic rat ventricular myocardium. Effect of different modulators of the cyclic GMP system. Pharmacol Toxicol 1993;72:56–60.CrossRefGoogle Scholar
  180. 180.
    Shah AM, Lewis MJ, Henderson AH. Effects of 8-bromo-cyclic GMP on contraction and on inotropic responses of ferret cardiac muscle. J Mol Cell Cardiol 1991;23:55–64.PubMedCrossRefGoogle Scholar
  181. 181.
    Shah AM, Evans HG, Lewis MJ. Phenylephrine-induced cardiac phosphatidylinositol (PI) hydrolysis is inhibited by cyclic GMP. Circulation 1990;82(Suppl III):III–270.Google Scholar
  182. 182.
    Bulmenthal DK, Stull JT, Gill GN. Phosphorylation of cardiac troponin by guanosine 3′:5′-monophosphate-dependent kinase. J Biol Chem 1978;253:334–336.Google Scholar
  183. 183.
    Lincoln TM, Corbin JD. Purified cyclic GMP-dependent protein kinase catalyzes the phosphorylation of cardiac troponin inhibitory subunit (TN-I). J Biol Chem 1978; 253:337–339.PubMedGoogle Scholar
  184. 184.
    Clement O, Puceat M, Vassort G. Protein kinases modulate Ca sensitivity of cardiac myofilaments in rat skinned cells. J Physiol (Loud) 1991;438:96P.Google Scholar
  185. 185.
    Van Renterghem C, Vigne P, Barhemin J, et al. Molecular mechanism of action of the vasoconstrictor peptide endothelin. Biochem Biophys Res Commun 1988; 157:977–985.PubMedCrossRefGoogle Scholar
  186. 186.
    Hendersen AH, Lewis MJ, Shah AM, et al. Endothelium, endocardium, and cardiac contraction. Cardiovasc Res 1992;26:305–308.CrossRefGoogle Scholar
  187. 187.
    Hofmann F, Dostmann W, Keilbach A, et al. Structure and physiological role of cGMP-dependent protein kinase. Biochim Biophys Acta 1992;1135:51–60.PubMedCrossRefGoogle Scholar
  188. 188.
    Axelsson KL, Karlsson J-O G, Pettersson G. Effect of glyceryl trinitrate and 8-Br-cGMP on tension and phosphorylase activity in vascular smooth muscle. Acta Pharmacol Toxicol 1985;57:227–233.CrossRefGoogle Scholar
  189. 189.
    Johnson RM, Lincoln TM. Effects of nitroprusside, glyceryl trinitrate, and 8-bromo cyclic GMP on phosphorylase a formation and myosin light chain phosphorylation in rat aorta. Mol Pharmacol 1985;27:333–342.PubMedGoogle Scholar
  190. 190.
    Lincoln TM, Cornwell TL, Rashatwar SS, et al. Mechanism of cyclic-GMP-dependent relaxation in vascular smooth muscle. Biochem Soc Transact 1988;16:497–499.Google Scholar
  191. 191.
    Kawahara Y, Yamanishi J, Fukuzaki H. Inhibitory action of guanosine 32032,52032-monophosphate on thrombin-induced cal-cium mobilization in human platelets. Thromb Res 1984;33:203–209.PubMedCrossRefGoogle Scholar
  192. 192.
    Lockette W, McCurdy R, Aronow, et al. Effect of 8-bromo-cyclic guanosine monophosphate on intracellular pH and calcium in vascular smooth muscle. Hypertension 1989;13:865–869.PubMedGoogle Scholar
  193. 193.
    Morgan RO, Newby AC. Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem J 1989;258:447–454.PubMedGoogle Scholar
  194. 194.
    Negrescu EV, Sazonova LN, Baldenkov GN, et al. Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure. Int J Cardiol 1990;26:175–184.PubMedCrossRefGoogle Scholar
  195. 195.
    Griin G, Fleckenstein A. Die elektromechanische Entkopplung der glatten Gefassmuskulatur als Grundprincip der Koronardilatation durch 4-(22032-nitrophenyl)-2,6-dimetyl-1, 4-dihydropyridin-3,5-dicarbonsaure-dimetyl ester (BAYa 10410, Nifedipine), Arzneim Forsch 1972;22:334–344.Google Scholar
  196. 196.
    Weder U, Griin G. Ca-antagonistische elektromechanische Entkopplung der glatten Gefassmuskulatur als Wirkung-sprincip vasodilatorischer Nitroverbindungen. Naunyn Schmiedebergs Arch Pharmacol 1973;277:R88.Google Scholar
  197. 197.
    Zoster TT, Jacyk P, Wolchinsky C. The effect of vasodilators on calcium kinetics in blood vessels. Arch Int Pharmacodyn 1974;212:328–336.Google Scholar
  198. 198.
    Zoster TT, Henein NF, Wolchinsky C. The effect of sodium nitroprusside on the uptake and efflux of 45Ca from rabbit and rat vessels. Eur J Pharmacol 1977;45:7–12.CrossRefGoogle Scholar
  199. 199.
    Hester RK, Weiss GB, Fry WJ. Differing actions of nitroprusside and D-600 on tension and 45Ca fluxes in canine renal arteries. J Pharmacol Exp Ther 1979;208:155–160.PubMedGoogle Scholar
  200. 200.
    Kreye VAW, Baron GD, Liith BJ, et al. Mode of action of sodium nitroprusside on vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 1975;288:381–402.PubMedCrossRefGoogle Scholar
  201. 201.
    Thorens S, Haeusler G. Effects of some vasodilators on calcium translocation in intact and fractionated vascular smooth muscle. Eur J Pharmacol 1979;54:71–91.CrossRefGoogle Scholar
  202. 202.
    Ahlner J, Axelsson KL, Karzewski P, et al. Studies on the effect of glyceryl trinitrate and cyclic GMP on calcium turnover in bovine mesenteric artery. Pharmacol Toxicol 1990;66:277–282.PubMedCrossRefGoogle Scholar
  203. 203.
    Nakazawa M, Imai S. Effect of nitroglycerin on Ca efflux in the coronary artery. Jpn J Pharmacol 1981;31:621–625.CrossRefGoogle Scholar
  204. 204.
    Ozaki H, Shibata S, Kitano H, et al. A comparative study of the effect of nitroprusside and verapamil on human umbilical vessels. Blood Vessels 1981;18:321–329.PubMedGoogle Scholar
  205. 205.
    Lincoln TM. Effects of nitroprusside and 8-Br-cyclic GMP on the contractile activity in the rat aorta. J Pharmacol Exp Ther 1983;224:100–107.PubMedGoogle Scholar
  206. 206.
    Twort CHA, Van Breemen C. Cyclic guanosine monophos-phate-enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988;62:961–964.PubMedGoogle Scholar
  207. 207.
    Nakashima S, Tohmatsu T, Hattori H, et al. Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem Biophys Res Commun 1986; 135:1099–1104.PubMedCrossRefGoogle Scholar
  208. 208.
    Fujii K, Ishimatsu T, Kuriyama H. Mechanism of vasodilation induced by a-human atrial natriuretic polypeptide in rabbit and guinea-pig renal arteries. J Physiol 1986;377:315–332.PubMedGoogle Scholar
  209. 209.
    Rapoport RM. Cyclic guanosine monophosphate inhibition of contraction may be mediated by through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ Res 1986;58:407–410.PubMedGoogle Scholar
  210. 210.
    Ahlner J, Axelsson KL, Karlsson J-O G, et al. Glyceryl trinitrate inhibits phosphatidyl inositol hydrolysis and protein kinase C activity in bovine mesenteric artery. Life Sci 1988;43:1241–1248.PubMedCrossRefGoogle Scholar
  211. 211.
    Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984;308:693–698.PubMedCrossRefGoogle Scholar
  212. 212.
    Movesian MA, Nishikawa M, Adelstein RS. Phosphorylation of phospholamban by calcium-activated, phospholipid-dependent protein kinase. J Biol Chem 1984;259:8029–8032.Google Scholar
  213. 213.
    Chiu A, Bozarth JM, Forsythe MS, et al. Ca++ utilization in the constriction of rat aorta to stimulation of protein kinase C by phorbol dibutyrate. J Pharmacol Exp Ther 1987;242:934–939.PubMedGoogle Scholar
  214. 214.
    Hagiwara M, Inagaki M, Watanabe M, et al. Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives. Mol Pharmacol 1987;32:7–12.PubMedGoogle Scholar
  215. 215.
    Hirata M, Kohse KP, Chang C-H, et al. Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J Biol Chem 1990;265:1268–1273.PubMedGoogle Scholar
  216. 216.
    Lincoln TM. Pertussis toxin-sensitive and insensitive guanine nucleotide binding proteins (G-proteins) are not phosphory-lated by cyclic GMP-dependent protein kinase. Second Messeng Phosphoprot 1991;13:99–109.Google Scholar
  217. 217.
    Popescu LM, Panoiu C, Hinescu M, et al. The mechanism of cGMP-induced relaxation in vascular smooth muscle. Eur J Pharmacol 1985;107:393–394.PubMedCrossRefGoogle Scholar
  218. 218.
    Furukawa K-I, Nakamura H. Cyclic GMP regulation of the plasma membrane (Ca2+-Mg2+)ATPase in vascular smooth muscle. J Biochem 1987;101:287–290.PubMedGoogle Scholar
  219. 219.
    Yoshida Y, Sun H-T, Cai J-Q, et al. Cyclic GMP-dependent protein kinase stimulates the plasma membrane Ca2+ pump ATPase of vascular smooth muscle via phosphorylation of a 240-kDa protein. J Biol Chem 1991;266:19819–19825.PubMedGoogle Scholar
  220. 220.
    Yanagisawa T, Kawada M, Taira N. Nitroglycerin relaxes canine coronary arterial smooth muscle without reducing intracellular Ca2+ concentrations measured with fura-2. Br J Pharmacol 1989;98:469–482.PubMedGoogle Scholar
  221. 221.
    Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983;306:174–176.PubMedCrossRefGoogle Scholar
  222. 222.
    Rapoport RM, Draznin MB, Murad F. Endothelium-dependent vasodilator- and nitrovasodilator-induced relaxation may be mediated through cyclic GMP formation and cyclic GMP-dependent protein phosphorylation. Trans Assoc Am Phys 1983;96:19–30.PubMedGoogle Scholar
  223. 223.
    Rapoport RM, Draznin MB, Murad F. Sodium nitroprusside-induced protein phosphorylation in intact rat aorta is mimicked by 8-bromo cyclic GMP. Proc Natl Acad Sci USA 1982;79:6470–6474.PubMedCrossRefGoogle Scholar
  224. 224.
    Draznin MB, Rapoport RM, Martinez GA, et al. Myosin light chain dephosphorylation in intact rat thoracic aorta treated with sodium nitroprusside: Role of cyclic GMP. Clin Res 1983;31:466A.Google Scholar
  225. 225.
    McDaniel NL, Chen X-L, Singer HA, et al. Nitrovasodilators relax arterial smooth muscle by decreasing [Ca21]i and uncoupling stress from myosin phosphorylation. Am J Physiol 1992;263:C461-C467.PubMedGoogle Scholar
  226. 226.
    Garg UC, Hassid A. Nitric oxide decreases cytosolic free calcium in Balb/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. J Biol Chem 1991;266:9–12.PubMedGoogle Scholar
  227. 227.
    Dimmeler S, Lottspeich F, Briine B. Nitric oxide causes ADP-ribosylation and inhibition of glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem 1992;267:16771–16774.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Kristina E. Torfgård
  • Johan Ahlner

There are no affiliations available

Personalised recommendations